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A B S T R A C T
We report a case of non-traumatic splenic rupture in a 57-year-old man on dual antiplatelet therapy
(DAPT) with aspirin and ticagrelor, seven months after percutaneous coronary intervention and drug-
eluting stent implantation for non-ST elevation myocardial infarction. No splenic abnormalities were
found at histopathological analysis after splenectomy, and no history of recent trauma was reported.
Once restarted, DAPT after splenectomy, assessment of platelet function was performed by light
transmittance aggregometry, showing a profound inhibition of platelet function by adenosine
diphosphate, arachidonic acid, and collagen. Taking into account the bleeding risk associated with
low on-treatment platelet reactivity, and to switch the patient from ticagrelor to a less potent P2Y12
inhibitor such as clopidogrel, cytochrome P450, genetic polymorphisms accounting for clopidogrel
response variability were analyzed. The polymorphisms associated with lower response (CYP2C19*2,
CYP2C19*3) were absent. Therefore, ticagrelor was withdrawn, and DAPT was continued with aspirin
and clopidogrel. Rupture of the spleen may occur in the absence of major trauma or previous splenic
diseases, and could be a complication of antithrombotic treatments. Moreover, low on-treatment
platelet reactivity during DAPT is emerging as a possible risk factor for bleeding complications, so
underlining the usefulness of assessing platelet function in special conditions to ensure that the patient
receives the best tailored antiplatelet therapy.
<Learning objective: Non-traumatic splenic rupture is a rare event, and is more often associated with
pre-existing splenic abnormalities. However, it may be also a complication of medical treatments,
especially with antithrombotic drugs. Low on-treatment platelet reactivity is emerging as a possible risk
factor for bleeding complications; therefore, assessing platelet function in special conditions could be
useful to ensure the patient receives the best-tailored antiplatelet therapy.>
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Rupture of the spleen is relatively common, both immediately
anddelayed,afterabdominaltrauma, whereasnon-traumaticsplenic
rupture is a rare event, and is more often associated with pathological
pre-existing splenic abnormalities. Among these, infarction due to
cardiac thromboembolism, infectious (i.e. malaria, mononucleosis),
inﬂammatory (i.e. immuno-rheumatologic), and inﬁltrative* Corresponding author at: Center for Atherothrombotic Diseases – AOU Careggi,
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liferative neoplasms) diseases have been reported in the literature as
the most frequent causes. However, cases of splenic rupture in the
absence of trauma or pathological pre-existing conditions, even less
frequent, have also been reported. A recent review of the literature
showed an association with medical procedures, such as colonosco-
py, and ongoing medical treatment with antithrombotic agents,
mainly anticoagulants and thrombolytic drugs, but also two cases
during antiplatelet therapy with ticlopidine [1–3].
Here, we report a case of non-traumatic rupture of the spleen in
a 57-year-old man on dual antiplatelet therapy (DAPT) with aspirin
and ticagrelor after percutaneous coronary intervention (PCI) and
new generation drug-eluting stent (DES) implantation for non-ST
elevation myocardial infarction. reserved.
Fig. 2.
Effect of dilution of platelet-rich plasma samples on light
transmittance aggregometry induced by adenosine diphosphate
(ADP) 10 mM, arachidonic acid (AA) 1 mM, and collagen 2 mg/mL.
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A 57-year-old man underwent PCI and new generation DES
implantation for non-ST elevation myocardial infarction with
angiographic demonstration of two-vessel coronary disease
(March 2014). DAPT with aspirin 100 mg once daily and ticagrelor
90 mg twice daily had been started soon after myocardial
revascularization, and initially planned to be continued for one
year. Seven months after the event, the patient came to medical
attention for sudden onset of abdominal pain and hypotension. An
abdomen computed tomography showed hemoperitoneum due to
splenic rupture. Urgent splenectomy was performed. No signs of
splenic infarction or other abnormalities (i.e. micro-aneurysms,
inﬂammatory or inﬁltrative disorders) were found at histopatho-
logical analysis of surgical specimen. No history of recent
abdominal trauma had been reported; neither clinical or biohu-
moral signs suggesting infectious or auto-immune diseases were
detected. Laboratory examination showed no signiﬁcant drop in
hemoglobin values, and also showed an increased white blood
cell and platelet count (17.3  109 L–1 and 1.222  109 L–1,
respectively), as expected after splenectomy. Antiplatelet therapy,
with aspirin soon after discharge, together with ticagrelor 15 days
later, was restarted. After 10 days, an assessment of platelet
function was performed by light transmittance aggregometry
(LTA) on platelet-rich plasma (PRP) with an APACT 4004 aggreg-
ometer (Axiom, Bursta¨dt, Germany) [4]. This test showed a
profound inhibition of platelet function by adenosine diphosphate
(ADP) 10 mM, arachidonic acid 1 mM, and collagen 2 mg/mL (LTA
14%, 11%, and 4%, respectively) (Fig. 1). To avoid confounding
results due to high platelet count (as normal response after
splenectomy), LTA test was repeated with different dilutions of
PRP samples, obtaining similar results. Platelet count at the time of
the ﬁrst analysis was 1.247  109 L–1. Platelet aggregation on the
undiluted, and diluted samples with a platelet count of
800  109 L–1 and 600  109 L–1 (which is the maximal platelet
count recommended for the APACT 4004 light transmittance
aggregometer), respectively, are reported in Fig. 2 [5–7]. Taking
into account the bleeding risk associated with low on-treatment
platelet reactivity and in order to switch the patient from ticagrelor
to a less potent P2Y12 inhibitor such as clopidogrel, genetic
polymorphisms accounting for clopidogrel response variability
were analyzed. Cytochrome P450 polymorphisms associated with
a lower response to clopidogrel administration (CYP2C19*2 and
CYP2C19*3 alleles) were absent, whereas homozygous
CYP2C19*17 polymorphism, which is on the contrary associated
with a higher response, was detected [8]. Moreover, no acquiredFig. 1.
Platelet aggregation on light transmittance aggregometry induced
by adenosine diphosphate (ADP) 10 mM, arachidonic acid (AA) 1 mM,
and collagen 2 mg/mL after restarting dual antiplatelet therapy with
aspirin and ticagrelor.clinical determinants of lower response to clopidogrel, such as
older age, diabetes, renal impairment, or heart failure, were
present in our patient. Therefore, taking into account both the
spontaneous nature of bleeding and laboratory test results, and
time elapsed from PCI and stent implantation (more than
6 months) together with the use of less thrombogenic new
generation DES, a decision was made to stop ticagrelor treatment
and continue DAPT with aspirin 100 mg and clopidogrel 75 mg
once daily. Fifteen days after starting clopidogrel, the percentage of
platelet aggregation on LTA, with a platelet count of 608  109 L–1,
was 35%, 12%, and 12% by ADP 10 mM, arachidonic acid 1 mM, and
collagen 2 mg/mL, respectively. No clinical, instrumental, or
laboratory signs raising suspicion of restenosis or stent thrombosis
after ticagrelor withdrawal were present. After two months of
DAPT with aspirin and clopidogrel, the patient remained asymp-
tomatic, hemoglobin values were stable, and abdomen computed
tomography did not show any pathological ﬁnding.
Discussion
Non-traumatic splenic rupture is a rare and life-threatening
cause of intraperitoneal hemorrhage, and is more often associated
with pre-existing splenic abnormalities. Among rare cases of
splenic rupture in the absence of trauma or pathological pre-
existing conditions, an association with ongoing medical treat-
ment with antithrombotic agents has also been reported [1–3]. To
the best of our knowledge, our case is the ﬁrst description of
splenic rupture during DAPT with aspirin and ticagrelor. Neither
recent traumatic abdominal injury had occurred, nor history of
infectious or auto-immune diseases had been reported in our
patient. Moreover, no inﬂammatory or inﬁltrative abnormalities of
the spleen were documented. DAPT was the only risk factor
associated with potential bleeding complications. The profound
inhibition of platelet function documented by LTA after restarting
treatment with aspirin and ticagrelor might have contributed
to the development of a splenic hematoma and consequent rupture
of the spleen. Indeed, there is a growing body of evidence that low
on-treatment platelet reactivity, induced by ADP and collagen,
during antiplatelet treatment with P2Y12 inhibitors is associated
with a higher risk of bleeding [9,10]. It has been postulated that
there is a therapeutic window for P2Y12 receptor blockers, thus
indicating that high on-treatment platelet reactivity is associated
with thrombotic events, whereas low on-treatment platelet
reactivity is associated with bleeding complications [10].
In conclusion, our case report underlines that rupture of the
spleen may occur even in the absence of major trauma or
E. Grifoni et al. / Journal of Cardiology Cases 12 (2015) 65–67 67previously diagnosed splenic diseases, and could be a complication
of medical treatments, especially with antithrombotic drugs.
Moreover, low on-treatment platelet reactivity during DAPT is
emerging as a possible risk factor for bleeding complications in
these patients, so underlining the usefulness of assessing platelet
function in special conditions, in order to ensure the patient
receives the best tailored antiplatelet therapy.
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